Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?

S Lista, BP Imbimbo, M Grasso, A Fidilio… - Journal of …, 2024 - Springer
Background Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including
lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have …

A critical appraisal of blood-based biomarkers for Alzheimer's disease

S Lista, M Mapstone, F Caraci, E Emanuele… - Ageing Research …, 2024 - Elsevier
Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …

A neuroimaging biomarker for Individual Brain-Related Abnormalities In Neurodegeneration (IBRAIN): a cross-sectional study

K Zhao, P Chen, A Alexander-Bloch, Y Wei… - …, 2023 - thelancet.com
Background Alzheimer's disease (AD) is a prevalent neurodegenerative disorder that poses
a worldwide public health challenge. A neuroimaging biomarker would significantly improve …

CSF and blood glial fibrillary acidic protein for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Y Zou, Y Wang, X Ma, D Mu, J Zhong, C Ma… - Ageing Research …, 2024 - Elsevier
Recently included in the 2024 new revised diagnostic criteria of Alzheimer's disease (AD),
glial fibrillary acidic protein (GFAP) has garnered significant attention. A systematic review …

Plasma biomarkers of Alzheimer's disease and neurodegeneration according to sociodemographic characteristics and chronic health conditions

HT Zheng, Z Wu, MM Mielke, AM Murray… - The Journal of Prevention …, 2024 - Springer
Ultrasensitive assays have been developed which enable biomarkers of Alzheimer's
disease pathology and neurodegeneration to be measured in blood. These biomarkers can …

Changes in Alzheimer disease blood biomarkers and associations with incident all-cause dementia

Y Lu, JR Pike, J Chen, KA Walker, KJ Sullivan… - JAMA, 2024 - jamanetwork.com
Importance Plasma biomarkers show promise for identifying Alzheimer disease (AD)
neuropathology and neurodegeneration, but additional examination among diverse …

A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease

T Chen, RM Hutchison, C Rubel, J Murphy… - The Journal of …, 2024 - Springer
Abstract Changes in biomarker levels of Alzheimer's disease (AD) reflect underlying
pathophysiological changes in the brain and can provide evidence of direct and …

Performance of SOBA-AD blood test in discriminating Alzheimer's disease patients from cognitively unimpaired controls in two independent cohorts

A Chen, D Shea, V Daggett - Scientific Reports, 2024 - nature.com
Amyloid-beta (Aβ) toxic oligomers are critical early players in the molecular pathology of
Alzheimer's disease (AD). We have developed a Soluble Oligomer Binding Assay (SOBA …

Precuneus activity during retrieval is positively associated with amyloid burden in cognitively normal older APOE4 carriers

L Fischer, EN Molloy, A Pichet Binette, N Vockert… - bioRxiv, 2024 - biorxiv.org
The precuneus is an early site of amyloid-beta accumulation. Previous cross-sectional
studies reported increased precuneus fMRI activity in older adults with mild cognitive deficits …

Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi‐ethnic Washington Heights–Hamilton Heights–Inwood …

Y Gu, LS Honig, MS Kang, A Bahl… - Alzheimer's & …, 2024 - Wiley Online Library
BACKGROUND Alzheimer's disease (AD) biomarkers can help differentiate cognitively
unimpaired (CU) individuals from mild cognitive impairment (MCI) and dementia. The role of …